EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Yuko Iida iD, Hirotsugu Kenmotsu, Keita Mori, Meiko Morita iD, Motoki Sekikawa, Michitoshi Yabe, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Nobuaki Mamesaya, Haruki Kobayashi und 8 weitere

Thoracic Cancer · 2026-04 · 17 (8)

DOI: 10.1111/1759-7714.70285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 24.04.2026. Verfasst von Yuko Iida und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of osimertinib in patients with postoperative recurrent non–small‐cell lung cancer (NSCLC) compared to those with Stage IV NSCLC harboring epidermal growth factor receptor ( EGFR ) mutations remains unclear.

Methods

This study evaluated the efficacy of osimertinib in patients with postoperative recurrent EGFR ‐mutated NSCLC. We retrospectively evaluated patients with NSCLC harboring EGFR mutations (exon 19 deletion or L858R mutation) who received osimertinib between September 2018 and July 2022 at a single institution. The efficacy of osimertinib was compared between patients with postoperative recurrent NSCLC (postoperative group) and those with Stage IV NSCLC (Stage IV group).

Results

Among a total of 172 patients treated with osimertinib, 52 were classified into the postoperative group and 120 into the Stage IV group. The response rate (58.1% vs. 61.8%, p = 0.836) and progression‐free survival (hazard ratio [HR]: 0.854, 95% confidence interval [CI]: 0.558–1.306, p = 0.465) were not significantly different between the postoperative and Stage IV groups. Overall survival (OS) was significantly longer in the postoperative group than in the Stage IV group (median: 39.2 months and 28.5 months, respectively; HR: 0.521, 95% CI: 0.293–0.927, p = 0.024). In the multivariable analysis of OS, postoperative recurrent disease and performance status were independent favorable prognostic factors.

Conclusions

Postoperative recurrent disease was an independent favorable prognostic factor in patients with NSCLC harboring EGFR mutations treated with osimertinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsCarcinoma, Non-Small-Cell LungAcrylamidesLung NeoplasmsNeoplasm Recurrence, LocalHumansIndolesPyrimidinesFemaleErbB ReceptorsMutationMaleRetrospective StudiesAgedMiddle AgedPrognosis

Stichwörter der Autor:innen

EGFRmutationnon–small‐cell lung cancerosimertinibpostoperative recurrent

Substanzen

osimertinibIndolesAniline CompoundsAcrylamidesPyrimidinesErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Department of Biostatistics, Clinical Research Support Center, Shizuoka Cancer Center, Shizuoka, Japan.
  • Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.

ORCID-Profile: Yuko Iida, Meiko Morita, Kazushige Wakuda, Tateaki Naito, Haruyasu Murakami

Zitieren

APA

Iida, Y., Kenmotsu, H., Mori, K., Morita, M., Sekikawa, M., Yabe, M., Doshita, K., Miura, K., Kodama, H., Morikawa, N., Mamesaya, N., Kobayashi, H., Ko, R., Wakuda, K., Ono, A., Naito, T., Murakami, H., Ohde, Y., Gon, Y., & Takahashi, T. (2026). Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations. Thoracic Cancer, 17(8). https://doi.org/10.1111/1759-7714.70285

Vancouver

Iida Y, Kenmotsu H, Mori K, Morita M, Sekikawa M, Yabe M, et al. Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations. Thoracic Cancer. 2026;17(8). doi:10.1111/1759-7714.70285

BibTeX
@article{Iida2026,
  author = {Iida, Yuko and Kenmotsu, Hirotsugu and Mori, Keita and Morita, Meiko and Sekikawa, Motoki and Yabe, Michitoshi and Doshita, Kosei and Miura, Keita and Kodama, Hiroaki and Morikawa, Noboru and Mamesaya, Nobuaki and Kobayashi, Haruki and Ko, Ryo and Wakuda, Kazushige and Ono, Akira and Naito, Tateaki and Murakami, Haruyasu and Ohde, Yasuhisa and Gon, Yasuhiro and Takahashi, Toshiaki},
  title = {Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {8},
  doi = {10.1111/1759-7714.70285}
}
Kostenlos starten →